{'output': [['Shire', 'COMP', 'Cut', '2020 Revenue Target', 'ECON_INDICATOR'], ['Shire', 'COMP', 'Prepare', 'Spin-off', 'ORG/REG'], ['Shire', 'COMP', 'Operate_In', 'Pharmaceutical Group', 'ORG'], ['Shire', 'COMP', 'Has', 'Rare Disease Business', 'SECTOR'], ['Shire', 'COMP', 'Has', 'Hyperactivity Medicines Business', 'SECTOR'], ['Shire', 'COMP', 'Face', 'Generic Competition', 'SECTOR'], ['Shire', 'COMP', 'Face', 'New Drugs from Rivals', 'SECTOR'], ['Shire', 'COMP', 'Drop', '$20 Billion Target', 'ECON_INDICATOR'], ['Shire', 'COMP', 'Operate_In', 'London', 'GPE'], ['Shire', 'COMP', 'Operate_In', 'Hematology', 'SECTOR'], ['Shire', 'COMP', 'Face', 'Additional Competition', 'SECTOR'], ['Shire', 'COMP', 'Has', 'Immunology Franchise', 'SECTOR'], ['Shire', 'COMP', 'Consider', 'Spin-off', 'ORG/REG'], ['Shire', 'COMP', 'Consider', 'Standalone Group', 'ORG/REG'], ['Shire', 'COMP', 'Evaluate', 'Independent Listing', 'ORG/REG'], ['Baxalta', 'COMP', 'Acquire', 'Shire', 'COMP'], ['Hemlibra', 'PRODUCT', 'Threaten', 'Shire Products', 'PRODUCT'], ['Lialda', 'PRODUCT', 'Have', 'Generic Competitor', 'PRODUCT'], ['Adderall', 'PRODUCT', 'Acquire', 'Shire', 'COMP'], ['Richwood Pharmaceutical', 'COMP', 'Acquire', 'Shire', 'COMP']]}